Although small‐molecule compounds that stabilize SHP2 autoinhibition (e.g., SHP099) hold great promise for targeting cancers involving SHP2, the inhibitory activity of these compounds against cancer‐associated SHP2‐activating mutants is greatly diminished because mutations in SHP2 disrupt their autoinhibitory conformation. Here, PTPN11 is linked to cancer.